One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
|Articles|January 1, 2008
Ideal length of androgen ablation for treatment of prostate cancer still debated
Although the observation is awaiting confirmation by more definitive data, it may be that in a select group of radiation-treated prostate cancer patients, 6 months of androgen ablation is as effective as a 3-year course of the adjuvant therapy in terms of cancer-specific survival.
Advertisement
Advertisement
Related to this article
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
Advertisement
Advertisement
Trending on Urology Times
1
The Evolving Landscape of Minimally Invasive BPH Therapy
2
TURP, HoLEP, and the Future of Minimally Invasive BPH Therapy
3
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
4
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
5